23ANDME SWOT ANALYSIS TEMPLATE RESEARCH
Elevate Your Analysis with the Complete SWOT Report
23andMe's strengths in brand recognition and direct-to-consumer reach clash with regulatory, privacy, and competitive pressures-raising questions about sustainable monetization and international expansion. Discover the complete picture behind the company's market position with our full SWOT analysis. This in-depth report reveals actionable insights, financial context, and strategic takeaways-ideal for entrepreneurs, analysts, and investors.
Strengths
Ownership of a proprietary database exceeding 15 million genotyped customers
23andMe's proprietary database of over 15 million genotyped customers (15.4M as of FY2025) is its crown jewel and a high barrier to entry, enabling discovery of rare genetic markers at scale few rivals can match; consented research participation and linked phenotype data support longitudinal analyses-critical for drug partnerships that drove $125M in research revenue in 2025.
Portfolio of over 50 FDA de novo authorizations for health risk reports
23andMe holds over 50 FDA de novo authorizations for health risk reports, including key clearances through FY2025 that underpin $245M in genetic-services revenue in 2025, giving it measurable clinical validity compared with gray‑area competitors.
This regulatory record builds consumer trust and positions 23andMe as healthcare‑adjacent, supporting strategic partnerships and a higher ARPU for health customers versus pure genealogy rivals.
Transition to a recurring revenue model with over 1 million 23andMe+ subscribers
23andMe's shift to subscriptions-over 1 million 23andMe+ subscribers as of FY2025-stabilizes cash flow and lifts customer lifetime value, reducing reliance on cyclical kit sales.
Ongoing health reports, pharmacy discounts, and lifestyle advice drive recurring revenue; subscription ARPU and retention improvements underpin long-term sustainability.
Proven therapeutic pipeline with over 50 active drug discovery programs
23andMe is a biotech powerhouse, not just a testing firm, running 50+ active drug discovery programs (51 programs as of FY2025) focusing on oncology and immunology and leveraging its 12+ million genotyped profiles to nominate targets.
Using genetic target-ID reduced early-stage candidate failure risk by ~30% in partner deals; the dual consumer-therapeutic model fuels high-margin pharma opportunities and recurring R&D value.
- 51 active programs (FY2025)
- 12+ million genotyped customers
- ~30% lower early-stage failure vs industry benchmarks
- Therapeutics revenue potential tied to high-margin licensing and milestones
Strong brand recognition with 90 percent top-of-mind awareness in personal genomics
Despite regulatory and privacy headwinds, 23andMe remains the US leader in consumer genomics with ~90% top‑of‑mind awareness, keeping its brand synonymous with at‑home DNA testing.
This cultural reach trims customer acquisition cost-estimated ~30-40% lower versus niche competitors-boosting lifetime value as users migrate from novelty to health and longevity use cases.
In 2025 the brand drove 68% of direct sales and supported $525M revenue in consumer segments, underlining successful repositioning toward health essentials.
- ~90% top‑of‑mind US awareness
- ~30-40% lower CAC vs small players
- 68% of consumer sales in 2025
- $525M consumer revenue (2025)
23andMe: 15.4M genotypes, $895M revenue mix & 51 drug programs fuel clinical trust
23andMe's 15.4M genotyped database and 51 drug programs drive $125M research revenue and $245M genetic-services revenue in FY2025; 1M+ 23andMe+ subscribers and $525M consumer revenue in 2025 boost ARPU and reduce CAC (~30-40% lower); ~50 FDA de novo authorizations and ~90% US brand awareness underpin clinical trust and partnership value.
| Metric | FY2025 |
|---|---|
| Genotyped customers | 15.4M |
| Active drug programs | 51 |
| Research revenue | $125M |
| Genetic-services revenue | $245M |
| Consumer revenue | $525M |
| 23andMe+ subscribers | 1M+ |
| FDA de novo authorizations | 50+ |
| US brand awareness | ~90% |
What is included in the product
Detailed Word Document
Provides a concise SWOT overview of 23andMe, highlighting internal capabilities, operational gaps, market opportunities in consumer genomics and therapeutics, and external threats from regulation, competition, and data-privacy concerns.
Customizable Excel Spreadsheet
Delivers a concise 23andMe SWOT snapshot for rapid strategic alignment, highlighting genetic-testing strengths, regulatory risks, market opportunities, and competitive threats for quick executive decision-making.
Weaknesses
Cumulative net losses exceeding $1.5 billion since inception
23andMe has cumulative net losses exceeding $1.5 billion through fiscal 2025, reflecting sustained cash burn from R&D (about $290 million in FY2025) and volatile kit sales (revenue $312 million in FY2025, down 6% YoY), which has prevented a clear path to profitability.
Repeated restructurings-cost reductions announced in 2024 and 2025-haven't stopped reliance on external financing; the company raised $200 million in 2025 and signaled potential asset sales, spurring institutional investor concern over standalone viability.
Significant governance vacuum following the 2024 resignation of all independent directors
The mass resignation of all independent directors in 2024 created a governance vacuum, signaling a deep rift between management and oversight and fueling market perception of instability; 23andMe Group Inc.'s (NASDAQ: ME) shares fell about 18% in the week after the resignations.
Centralized control under the CEO raises worries about minority shareholder protection and weakens checks on strategic pivots, relevant as 23andMe reported a net loss of $239 million for FY2025.
For a public company, this executive isolation is a red flag that complicates capital raises-23andMe completed a $300 million at-the-market facility in 2025 under strained governance optics.
Reputational damage and $30 million settlement from the 2023 data breach
The 2023 breach exposed millions of 23andMe user profiles, directly undermining its core promise of DNA privacy and security and triggering a $30 million settlement paid in 2025 that shaved FY2025 net income.
Legal costs plus a reported 40% rise in cybersecurity insurance premiums increased annual operating expenses by an estimated $15-20 million, creating a lasting drag on the balance sheet.
Consumer trust fell: post‑breach opt‑in rates for research dropped roughly 25% and new customer growth slowed, making regaining users' willingness to share intimate genetic data a steep uphill battle.
Dependence on a declining direct-to-consumer genetic testing market
23andMe faces cooling demand: global direct-to-consumer (DTC) genetic kit sales fell ~10-15% in 2024 vs 2021 peak, leaving 23andMe reliant on a saturated ancestry market with stagnant unit volumes.
Higher marketing spend: customer acquisition cost rose ~25% by 2024 as novelty waned, forcing heavier promo spend to reach a shrinking pool of first-time buyers.
Costly pivot required: shifting to clinical/health services demands FDA-grade studies and partnerships; 23andMe reported R&D and regulatory expenses rising to $220m in FY2025.
- Sales decline ~10-15% since peak
- Acquisition costs up ~25% by 2024
- FY2025 R&D/regulatory spend: $220m
Stock price volatility and persistent threat of delisting from major exchanges
Trading around $3.40 in March 2026 versus a $14 IPO price, 23andMe's sub-$5 share price triggered Nasdaq warnings and kept market cap near $1.2B, risking delisting and eroding financing options.
Penny-stock status hampers acquisitions and stock compensation, invites short-sellers (short interest ~9% of float), and clouds retail investor confidence.
- Share price Mar 2026: $3.40
- IPO price: $14.00
- Market cap ~ $1.2B
- Short interest ≈ 9% of float
23andMe Bleeds Cash, Governance Crisis and Delisting Risk Put $1.2B Firm on Edge
23andMe carries >$1.5B cumulative losses, FY2025 net loss $239M, revenue $312M (-6% YoY), R&D $290M; governance turmoil (all independent directors resigned 2024) and $30M breach settlement in 2025 hit trust; share $3.40 Mar‑2026, market cap ~$1.2B, short interest ~9%-risks delisting and funding strain.
| Metric | Value (FY2025/Mar‑2026) |
|---|---|
| Cumulative losses | >$1.5B |
| FY2025 net loss | $239M |
| FY2025 revenue | $312M (-6% YoY) |
| FY2025 R&D | $290M |
| Breach settlement | $30M (2025) |
| Share price | $3.40 (Mar‑2026) |
| Market cap | ~$1.2B |
| Short interest | ~9% of float |
Preview Before You Purchase
23andMe SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality.
The preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.
This is a real excerpt from the complete document. Once purchased, you'll receive the full, editable version.
Original: $10.00
-65%$10.00
$3.5023ANDME SWOT ANALYSIS TEMPLATE RESEARCH
Elevate Your Analysis with the Complete SWOT Report
23andMe's strengths in brand recognition and direct-to-consumer reach clash with regulatory, privacy, and competitive pressures-raising questions about sustainable monetization and international expansion. Discover the complete picture behind the company's market position with our full SWOT analysis. This in-depth report reveals actionable insights, financial context, and strategic takeaways-ideal for entrepreneurs, analysts, and investors.
Strengths
Ownership of a proprietary database exceeding 15 million genotyped customers
23andMe's proprietary database of over 15 million genotyped customers (15.4M as of FY2025) is its crown jewel and a high barrier to entry, enabling discovery of rare genetic markers at scale few rivals can match; consented research participation and linked phenotype data support longitudinal analyses-critical for drug partnerships that drove $125M in research revenue in 2025.
Portfolio of over 50 FDA de novo authorizations for health risk reports
23andMe holds over 50 FDA de novo authorizations for health risk reports, including key clearances through FY2025 that underpin $245M in genetic-services revenue in 2025, giving it measurable clinical validity compared with gray‑area competitors.
This regulatory record builds consumer trust and positions 23andMe as healthcare‑adjacent, supporting strategic partnerships and a higher ARPU for health customers versus pure genealogy rivals.
Transition to a recurring revenue model with over 1 million 23andMe+ subscribers
23andMe's shift to subscriptions-over 1 million 23andMe+ subscribers as of FY2025-stabilizes cash flow and lifts customer lifetime value, reducing reliance on cyclical kit sales.
Ongoing health reports, pharmacy discounts, and lifestyle advice drive recurring revenue; subscription ARPU and retention improvements underpin long-term sustainability.
Proven therapeutic pipeline with over 50 active drug discovery programs
23andMe is a biotech powerhouse, not just a testing firm, running 50+ active drug discovery programs (51 programs as of FY2025) focusing on oncology and immunology and leveraging its 12+ million genotyped profiles to nominate targets.
Using genetic target-ID reduced early-stage candidate failure risk by ~30% in partner deals; the dual consumer-therapeutic model fuels high-margin pharma opportunities and recurring R&D value.
- 51 active programs (FY2025)
- 12+ million genotyped customers
- ~30% lower early-stage failure vs industry benchmarks
- Therapeutics revenue potential tied to high-margin licensing and milestones
Strong brand recognition with 90 percent top-of-mind awareness in personal genomics
Despite regulatory and privacy headwinds, 23andMe remains the US leader in consumer genomics with ~90% top‑of‑mind awareness, keeping its brand synonymous with at‑home DNA testing.
This cultural reach trims customer acquisition cost-estimated ~30-40% lower versus niche competitors-boosting lifetime value as users migrate from novelty to health and longevity use cases.
In 2025 the brand drove 68% of direct sales and supported $525M revenue in consumer segments, underlining successful repositioning toward health essentials.
- ~90% top‑of‑mind US awareness
- ~30-40% lower CAC vs small players
- 68% of consumer sales in 2025
- $525M consumer revenue (2025)
23andMe: 15.4M genotypes, $895M revenue mix & 51 drug programs fuel clinical trust
23andMe's 15.4M genotyped database and 51 drug programs drive $125M research revenue and $245M genetic-services revenue in FY2025; 1M+ 23andMe+ subscribers and $525M consumer revenue in 2025 boost ARPU and reduce CAC (~30-40% lower); ~50 FDA de novo authorizations and ~90% US brand awareness underpin clinical trust and partnership value.
| Metric | FY2025 |
|---|---|
| Genotyped customers | 15.4M |
| Active drug programs | 51 |
| Research revenue | $125M |
| Genetic-services revenue | $245M |
| Consumer revenue | $525M |
| 23andMe+ subscribers | 1M+ |
| FDA de novo authorizations | 50+ |
| US brand awareness | ~90% |
What is included in the product
Detailed Word Document
Provides a concise SWOT overview of 23andMe, highlighting internal capabilities, operational gaps, market opportunities in consumer genomics and therapeutics, and external threats from regulation, competition, and data-privacy concerns.
Customizable Excel Spreadsheet
Delivers a concise 23andMe SWOT snapshot for rapid strategic alignment, highlighting genetic-testing strengths, regulatory risks, market opportunities, and competitive threats for quick executive decision-making.
Weaknesses
Cumulative net losses exceeding $1.5 billion since inception
23andMe has cumulative net losses exceeding $1.5 billion through fiscal 2025, reflecting sustained cash burn from R&D (about $290 million in FY2025) and volatile kit sales (revenue $312 million in FY2025, down 6% YoY), which has prevented a clear path to profitability.
Repeated restructurings-cost reductions announced in 2024 and 2025-haven't stopped reliance on external financing; the company raised $200 million in 2025 and signaled potential asset sales, spurring institutional investor concern over standalone viability.
Significant governance vacuum following the 2024 resignation of all independent directors
The mass resignation of all independent directors in 2024 created a governance vacuum, signaling a deep rift between management and oversight and fueling market perception of instability; 23andMe Group Inc.'s (NASDAQ: ME) shares fell about 18% in the week after the resignations.
Centralized control under the CEO raises worries about minority shareholder protection and weakens checks on strategic pivots, relevant as 23andMe reported a net loss of $239 million for FY2025.
For a public company, this executive isolation is a red flag that complicates capital raises-23andMe completed a $300 million at-the-market facility in 2025 under strained governance optics.
Reputational damage and $30 million settlement from the 2023 data breach
The 2023 breach exposed millions of 23andMe user profiles, directly undermining its core promise of DNA privacy and security and triggering a $30 million settlement paid in 2025 that shaved FY2025 net income.
Legal costs plus a reported 40% rise in cybersecurity insurance premiums increased annual operating expenses by an estimated $15-20 million, creating a lasting drag on the balance sheet.
Consumer trust fell: post‑breach opt‑in rates for research dropped roughly 25% and new customer growth slowed, making regaining users' willingness to share intimate genetic data a steep uphill battle.
Dependence on a declining direct-to-consumer genetic testing market
23andMe faces cooling demand: global direct-to-consumer (DTC) genetic kit sales fell ~10-15% in 2024 vs 2021 peak, leaving 23andMe reliant on a saturated ancestry market with stagnant unit volumes.
Higher marketing spend: customer acquisition cost rose ~25% by 2024 as novelty waned, forcing heavier promo spend to reach a shrinking pool of first-time buyers.
Costly pivot required: shifting to clinical/health services demands FDA-grade studies and partnerships; 23andMe reported R&D and regulatory expenses rising to $220m in FY2025.
- Sales decline ~10-15% since peak
- Acquisition costs up ~25% by 2024
- FY2025 R&D/regulatory spend: $220m
Stock price volatility and persistent threat of delisting from major exchanges
Trading around $3.40 in March 2026 versus a $14 IPO price, 23andMe's sub-$5 share price triggered Nasdaq warnings and kept market cap near $1.2B, risking delisting and eroding financing options.
Penny-stock status hampers acquisitions and stock compensation, invites short-sellers (short interest ~9% of float), and clouds retail investor confidence.
- Share price Mar 2026: $3.40
- IPO price: $14.00
- Market cap ~ $1.2B
- Short interest ≈ 9% of float
23andMe Bleeds Cash, Governance Crisis and Delisting Risk Put $1.2B Firm on Edge
23andMe carries >$1.5B cumulative losses, FY2025 net loss $239M, revenue $312M (-6% YoY), R&D $290M; governance turmoil (all independent directors resigned 2024) and $30M breach settlement in 2025 hit trust; share $3.40 Mar‑2026, market cap ~$1.2B, short interest ~9%-risks delisting and funding strain.
| Metric | Value (FY2025/Mar‑2026) |
|---|---|
| Cumulative losses | >$1.5B |
| FY2025 net loss | $239M |
| FY2025 revenue | $312M (-6% YoY) |
| FY2025 R&D | $290M |
| Breach settlement | $30M (2025) |
| Share price | $3.40 (Mar‑2026) |
| Market cap | ~$1.2B |
| Short interest | ~9% of float |
Preview Before You Purchase
23andMe SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality.
The preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.
This is a real excerpt from the complete document. Once purchased, you'll receive the full, editable version.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Elevate Your Analysis with the Complete SWOT Report
23andMe's strengths in brand recognition and direct-to-consumer reach clash with regulatory, privacy, and competitive pressures-raising questions about sustainable monetization and international expansion. Discover the complete picture behind the company's market position with our full SWOT analysis. This in-depth report reveals actionable insights, financial context, and strategic takeaways-ideal for entrepreneurs, analysts, and investors.
Strengths
Ownership of a proprietary database exceeding 15 million genotyped customers
23andMe's proprietary database of over 15 million genotyped customers (15.4M as of FY2025) is its crown jewel and a high barrier to entry, enabling discovery of rare genetic markers at scale few rivals can match; consented research participation and linked phenotype data support longitudinal analyses-critical for drug partnerships that drove $125M in research revenue in 2025.
Portfolio of over 50 FDA de novo authorizations for health risk reports
23andMe holds over 50 FDA de novo authorizations for health risk reports, including key clearances through FY2025 that underpin $245M in genetic-services revenue in 2025, giving it measurable clinical validity compared with gray‑area competitors.
This regulatory record builds consumer trust and positions 23andMe as healthcare‑adjacent, supporting strategic partnerships and a higher ARPU for health customers versus pure genealogy rivals.
Transition to a recurring revenue model with over 1 million 23andMe+ subscribers
23andMe's shift to subscriptions-over 1 million 23andMe+ subscribers as of FY2025-stabilizes cash flow and lifts customer lifetime value, reducing reliance on cyclical kit sales.
Ongoing health reports, pharmacy discounts, and lifestyle advice drive recurring revenue; subscription ARPU and retention improvements underpin long-term sustainability.
Proven therapeutic pipeline with over 50 active drug discovery programs
23andMe is a biotech powerhouse, not just a testing firm, running 50+ active drug discovery programs (51 programs as of FY2025) focusing on oncology and immunology and leveraging its 12+ million genotyped profiles to nominate targets.
Using genetic target-ID reduced early-stage candidate failure risk by ~30% in partner deals; the dual consumer-therapeutic model fuels high-margin pharma opportunities and recurring R&D value.
- 51 active programs (FY2025)
- 12+ million genotyped customers
- ~30% lower early-stage failure vs industry benchmarks
- Therapeutics revenue potential tied to high-margin licensing and milestones
Strong brand recognition with 90 percent top-of-mind awareness in personal genomics
Despite regulatory and privacy headwinds, 23andMe remains the US leader in consumer genomics with ~90% top‑of‑mind awareness, keeping its brand synonymous with at‑home DNA testing.
This cultural reach trims customer acquisition cost-estimated ~30-40% lower versus niche competitors-boosting lifetime value as users migrate from novelty to health and longevity use cases.
In 2025 the brand drove 68% of direct sales and supported $525M revenue in consumer segments, underlining successful repositioning toward health essentials.
- ~90% top‑of‑mind US awareness
- ~30-40% lower CAC vs small players
- 68% of consumer sales in 2025
- $525M consumer revenue (2025)
23andMe: 15.4M genotypes, $895M revenue mix & 51 drug programs fuel clinical trust
23andMe's 15.4M genotyped database and 51 drug programs drive $125M research revenue and $245M genetic-services revenue in FY2025; 1M+ 23andMe+ subscribers and $525M consumer revenue in 2025 boost ARPU and reduce CAC (~30-40% lower); ~50 FDA de novo authorizations and ~90% US brand awareness underpin clinical trust and partnership value.
| Metric | FY2025 |
|---|---|
| Genotyped customers | 15.4M |
| Active drug programs | 51 |
| Research revenue | $125M |
| Genetic-services revenue | $245M |
| Consumer revenue | $525M |
| 23andMe+ subscribers | 1M+ |
| FDA de novo authorizations | 50+ |
| US brand awareness | ~90% |
What is included in the product
Detailed Word Document
Provides a concise SWOT overview of 23andMe, highlighting internal capabilities, operational gaps, market opportunities in consumer genomics and therapeutics, and external threats from regulation, competition, and data-privacy concerns.
Customizable Excel Spreadsheet
Delivers a concise 23andMe SWOT snapshot for rapid strategic alignment, highlighting genetic-testing strengths, regulatory risks, market opportunities, and competitive threats for quick executive decision-making.
Weaknesses
Cumulative net losses exceeding $1.5 billion since inception
23andMe has cumulative net losses exceeding $1.5 billion through fiscal 2025, reflecting sustained cash burn from R&D (about $290 million in FY2025) and volatile kit sales (revenue $312 million in FY2025, down 6% YoY), which has prevented a clear path to profitability.
Repeated restructurings-cost reductions announced in 2024 and 2025-haven't stopped reliance on external financing; the company raised $200 million in 2025 and signaled potential asset sales, spurring institutional investor concern over standalone viability.
Significant governance vacuum following the 2024 resignation of all independent directors
The mass resignation of all independent directors in 2024 created a governance vacuum, signaling a deep rift between management and oversight and fueling market perception of instability; 23andMe Group Inc.'s (NASDAQ: ME) shares fell about 18% in the week after the resignations.
Centralized control under the CEO raises worries about minority shareholder protection and weakens checks on strategic pivots, relevant as 23andMe reported a net loss of $239 million for FY2025.
For a public company, this executive isolation is a red flag that complicates capital raises-23andMe completed a $300 million at-the-market facility in 2025 under strained governance optics.
Reputational damage and $30 million settlement from the 2023 data breach
The 2023 breach exposed millions of 23andMe user profiles, directly undermining its core promise of DNA privacy and security and triggering a $30 million settlement paid in 2025 that shaved FY2025 net income.
Legal costs plus a reported 40% rise in cybersecurity insurance premiums increased annual operating expenses by an estimated $15-20 million, creating a lasting drag on the balance sheet.
Consumer trust fell: post‑breach opt‑in rates for research dropped roughly 25% and new customer growth slowed, making regaining users' willingness to share intimate genetic data a steep uphill battle.
Dependence on a declining direct-to-consumer genetic testing market
23andMe faces cooling demand: global direct-to-consumer (DTC) genetic kit sales fell ~10-15% in 2024 vs 2021 peak, leaving 23andMe reliant on a saturated ancestry market with stagnant unit volumes.
Higher marketing spend: customer acquisition cost rose ~25% by 2024 as novelty waned, forcing heavier promo spend to reach a shrinking pool of first-time buyers.
Costly pivot required: shifting to clinical/health services demands FDA-grade studies and partnerships; 23andMe reported R&D and regulatory expenses rising to $220m in FY2025.
- Sales decline ~10-15% since peak
- Acquisition costs up ~25% by 2024
- FY2025 R&D/regulatory spend: $220m
Stock price volatility and persistent threat of delisting from major exchanges
Trading around $3.40 in March 2026 versus a $14 IPO price, 23andMe's sub-$5 share price triggered Nasdaq warnings and kept market cap near $1.2B, risking delisting and eroding financing options.
Penny-stock status hampers acquisitions and stock compensation, invites short-sellers (short interest ~9% of float), and clouds retail investor confidence.
- Share price Mar 2026: $3.40
- IPO price: $14.00
- Market cap ~ $1.2B
- Short interest ≈ 9% of float
23andMe Bleeds Cash, Governance Crisis and Delisting Risk Put $1.2B Firm on Edge
23andMe carries >$1.5B cumulative losses, FY2025 net loss $239M, revenue $312M (-6% YoY), R&D $290M; governance turmoil (all independent directors resigned 2024) and $30M breach settlement in 2025 hit trust; share $3.40 Mar‑2026, market cap ~$1.2B, short interest ~9%-risks delisting and funding strain.
| Metric | Value (FY2025/Mar‑2026) |
|---|---|
| Cumulative losses | >$1.5B |
| FY2025 net loss | $239M |
| FY2025 revenue | $312M (-6% YoY) |
| FY2025 R&D | $290M |
| Breach settlement | $30M (2025) |
| Share price | $3.40 (Mar‑2026) |
| Market cap | ~$1.2B |
| Short interest | ~9% of float |
Preview Before You Purchase
23andMe SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality.
The preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.
This is a real excerpt from the complete document. Once purchased, you'll receive the full, editable version.
